Gregory Maes: Liquid biopsy for non-invasive cancer detection
Gregory Maes, Global Pharma and Strategic Alliances Manager at Nonacus, posted the following on LinkedIn:
“A great new concise article discussing the clinical applications of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).
Liquid biopsy has received tremendous attention as a non-invasive approach for detecting and tracking cancer.
The article authored by liquid biopsy experts Catherine Alix-Panabières and Klaus Pantel discusses the latest work on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) with respect to clinical applications, including cancer screening, early detection of relapse, real-time monitoring of therapeutic efficacy, and detection of therapeutic targets and resistance mechanisms.
Free ACCESS.
Happy reading!”
Advances in liquid biopsy: From exploration to practical application
Authors: Catherine Alix-Panabières, Klaus Pantel
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023